Related Experiment Video
Updated: Jul 19, 2026

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
Published on: May 28, 2019
Intracoronary infusion of levosimendan to treat postpericardiotomy heart failure
Philippe-Primo Caimmi1, Elena Grossini, Claudio Molinari
1Department of Cardiac Surgery, Ospedale Maggiore della Carità, School of Medicine, University of East Piedmont A. Avogadro, Novara, Italy. philippe.caimmi@med.unipmn.it
Insights
Intracoronary levosimendan administration in heart failure patients may improve cardiac function and graft blood flow without causing systemic hypotension. This approach offers a potential alternative for patients with coronary disease.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Systemic hypotension restricts intravenous levosimendan use, especially in coronary artery disease.
- Intracoronary levosimendan in animal models increased coronary blood flow without systemic hypotension.
Observation:
- A case report details intracoronary levosimendan bolus administration in a 74-year-old male patient with postpericardiotomy heart failure.
- The patient experienced no changes in heart rate or systemic arterial blood pressure.
Findings:
- Beneficial cardiac effects were observed, including improved systolic and diastolic functions.
- Blood flow in all coronary grafts increased following administration.
Implications:
- Intracoronary levosimendan demonstrates potential as a localized treatment for heart failure in specific patient populations.
- This route may overcome the limitations of intravenous administration, particularly in patients with compromised cardiovascular systems.
Abstract:
Systemic hypotension limits the intravenous use of levosimendan, particularly in coronary disease. Published reports show that the intracoronary administration of levosimendan in animal models causes an increase of coronary blood flow without systemic hypotension. In this case report, the intracoronary administration of levosimendan bolus in a 74-year-old man with postpericardiotomy heart failure elicited beneficial cardiac effects, increasing both systolic and diastolic functions and blood flow in all of the grafts. No changes of heart rate and systemic arterial blood pressure were observed.
Related Concept Videos
Heart Failure Drugs: Inotropic Agents
Cardiomyopathy V: Interprofessional Care
Acute Coronary Syndrome IV: Interprofessional Care
Acute Coronary Syndrome V: Nursing Management
Heart Failure VI: Adjunct Therapies
Cardiomyopathy VII: Pre and Post Operative Nursing Management
